Rinvoq Description

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Full Prescribing Info

Description

RINVOQ 15 mg extended-release tablets: Each extended-release tablet contains upadacitinib hemihydrate, equivalent to 15 mg of upadacitinib.
RINVOQ 30 mg extended-release tablets: Each extended-release tablet contains upadacitinib hemihydrate, equivalent to 30 mg of upadacitinib.
Excipients/Inactive Ingredients: Tablet contents: Microcrystalline cellulose, Hypromellose, Mannitol, Tartaric acid, Colloidal anhydrous silica, Magnesium stearate.
Film coating: Poly(vinyl alcohol), Macrogol, Talc, Titanium dioxide (E171), Iron oxide black (E172) (15 mg strength only), Iron oxide red (E172).

upadacitinib

Manufacturer:

AbbVie

Distributor:

Zuellig Pharma